Towards Healthcare
Intranasal Corticosteroids Market to Surge USD 11.57 Bn by 2034

Intranasal Corticosteroids Market Driven by New Innovations

According to forecasts, the global intranasal corticosteroids market will grow from USD 7.22 billion in 2024 to USD 11.57 billion by 2034, with an expected CAGR of 4.84%. The globally rising prevalence of chronic rhinitis due to the expanding urbanization and industrialization is demanding INCs. North America dominated the market due to its fostering innovations in novel delivery systems.

Content

  • Last Updated: 13 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The intranasal corticosteroids market currently in 2025 records USD 7.57 billion and is anticipated to grow to USD 11.57 billion by 2034, advancing at a CAGR of 4.84% from 2024 to 2034.

North America is currently leading the intranasal corticosteroids market due to the rising emphasis on OTC availability and innovations in drug delivery.

Some key players include GlaxoSmithKline plc, Sanofi, AstraZeneca, Johnson & Johnson, and Pfizer.

Burning or stinging is the most common adverse effect of INCs.

US FDA, NIH, Clinicaltrials.gov, MedlinePlus.gov, GOV.UK, Medicaid.nv.gov, moh.gov.sa, AOI.
Any Questions